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ABSTRACT  
Injecting behaviour in people who inject drugs is the main risk factor for hepatitis C virus (HCV) 
infection. Psychosocial factors such as having a partner who injects drugs and living with other drug 
users have been associated with increases in injecting risk behaviour. This study aimed to investigate 
changes in injecting behaviour during treatment for HCV infection whilst exploring the role of 
psychosocial factors on patients’ injecting behaviour. Eradicate-C was a single centred clinical trial 
(ISRCTN27564683) investigating the effectiveness of HCV treatment within the injecting drug using 
population between 2012 and 2017. A total of 94 participants completed up to 24 weeks of treatment, 
with social and behavioural measures taken at different intervals throughout treatment. Data for 84 
participants was analysed retrospectively to explore mechanisms of potential behavioural changes 
which had occurred during treatment.Injecting frequency reduced significantly between baseline 
(week 1) and every 4-weekly interval until week 26. Not being on Opiate Substitution Therapy (OST) 
was associated with a statistically significant decrease in injecting frequency, χ2 (1) = 10.412, p =.001, 
as was having a partner who also used drugs, in particular when that partner was also on treatment 
for HCV infection, Z= -2.312, p=.021. Treating a ‘ hard-to-reach population for HCV infection is not 
only possible, but also bears health benefits beyond treatment of HCV alone. Enrolling couples on 
HCV treatment when partners are sero-concordant, has shown enhanced benefits for reduction in 
injecting behaviour. Implications for practice are discussed. 
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Over 71 million people worldwide are chronically infected with the hepatitis C virus [1-2]. The disease 
burden is axiomatic, with an estimated HCV-related mortality of 400,000 people a year [1]. The most 
common transmission route in Western countries remains injecting drug use, with an estimated 60-
80% of the HCV-positive population having acquired the virus via injecting risk behaviour [3-5]. A 
variety of psychosocial factors have been associated with injecting risk behaviour: injecting frequency, 
poly-drug use, having a sexual partner who also injects, trust and risk perception to name a few [6-8]. 
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shown that fears of non-adherence and low sustained-virological response (SVR) rates are 
unjustified, with people who inject drugs (PWID) showing both successful adherence and high SVR 
rates [3, 9-10]. 
Psychosocial factors seem to have conflicting effects on injecting risk behaviour and HCV treatment 
success. Published literature reports an association between HCV treatment success rates and social 
support [11]. Peers help to increase motivation, feelings of hope and strength to complete treatment, 
as well as decreasing internalised stigma and shame related to HCV and substance misuse, reducing 
use of substances itself [12-13]. Yet, historically, close relationships with other PWID, such as 
romantic partnerships and living with other drug users, are among the factors most strongly linked to 
continued injecting risk behaviour [6-8].  A possible explanation of these polar effects could be that in 
a hostile environment where the behaviours of vulnerable adults are influenced negatively by 
partners, a positive sense of acceptance, belonging and self-worth can stem from these partnerships 
[14]. Integrated models of behaviour change attempt to explain how couple dynamics can influence 
risk and health behaviours [15]. 
HCV treatment itself seems to have a wider effect on PWID than curing hepatitis C alone. It has been 
associated with a decrease in ancillary injecting equipment sharing after treatment completion [16], 
suggesting treatment might impact the injecting behavoiur as well as HCV. Midgard and colleagues 
[17] investigated changes in behaviour during and after treatment, and reported a decrease in recent 
injecting drug use, alcohol use and an increase in opiate substitution therapy (OST) uptake 
throughout HCV treatment and at follow-up. However, they found no changes in daily injecting, use of 
sterile or shared equipment [17]. Only a few studies have investigated the effects of HCV treatment 
on risk behaviour [16-17] and no literature to date has investigated the role of psychosocial factors 
such as romantic partnerships and living situation on risk behaviour during and following HCV 
treatment. 
The Eradicate-C study was carried out to investigate the effectiveness of interferon-based HCV 
treatment on current PWID, characterised by a strenuous lifestyle and erratic engagement with 
healthcare services. This study aimed to investigate changes in injecting behaviour during treatment, 
examining the role of psychosocial factors on hypothesised injecting behaviour change. 
Methods  
Study design 
Eradicate-C was a single centred clinical trial investigating the effectiveness of HCV treatment within 
the injecting drug using population between 2012 and 2017. Participants were seen on a weekly basis 
for 26 consecutive weeks for treatment and the additional period of follow-up. The nurses, starting on 
visit 2 of the study, provided a weekly injection of 180µg pegylated interferon α (PEG-IFNα) and 
supplied participants with a week’s worth take-home daily dose of between 400 – 1400 mg (weight 
based) of self-administered ribavirin (RBV).  Patients presenting with a genotype 1 infection, also 
received protease inhibitors: telaprevir or simeprevir. The study treatment mirrored the standard of 
care treatment duration of 24 weeks for genotype 1 infections and of 16 weeks for genotypes 2 and 3 
infections. All participants completed behavioural and social measures at different time points during 
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The study was conducted in accordance with the Declaration of Helsinki and the principles of good 
clinical practice (GCP). The study was co-sponsored by the University of Dundee and NHS Tayside, 
and was ethically reviewed and approved by the East of Scotland Research Ethics Service REC 2. It 
was also registered with the National Institute for Health Research (NIHR) on UK Clinical Trials 
Gateway as ISRCTN27564683. 
Outcomes 
The primary outcome of the Eradicate-C study was to analyse SVR12 in the PWID population, which 
resulted in an 81.1% genotype 1 and 82.5% genotype 2 & 3 achieving SVR. The total SVR12 rate for 
all participants was 81.9%.  
In this paper, the outcomes of interest were the behavioural and social measures collected during 
treatment. The primary outcome was injecting frequency throughout treatment (collected at visit 1, 4, 
8, 12, 20, 24 and 26). Independent variables analysed were OST, living situation, living with other 
drug users, having children, having a partner, having a partner who used drugs/alcohol and the EQ5D 
scores. These measures were taken at visit 1 and visit 26, with the exception of OST, taken every 
visit from visit 2 to follow up (visits 27 and 28). 
Study participants  
A total of 94 participants completed up to 24 weeks of treatment between January 2013 and 
December 2016 within the largest Injecting Equipment Provision (IEP) service in Dundee (Scotland, 
UK). Participants were aged between 18 and 70 years, had an active HCV infection and reported 
current illicit drug use (defined as those who had injected in the past 4 weeks)which was confirmed 
through injection sites inspection.This study analysed behavioural and social data from visit 1 and visit 
8 of treatment. Not all 94 participants who completed treatment provided data for both visits, reducing 
the pool of participants to 84 for the present analysis. 
Analysis 
Data was analysed using IBM SPSS Statistics 22. Descriptive analyses were run to obtain 
characteristics of the sample. If data was missing for one visit (e.g. visit 8) but available for 
immediately preceding and subsequent weeks (e.g. visits 7 and 9), an average score was used for 
the required missing visit. If immediately preceding and subsequent visit scores were not available, 
data was considered missing.  Non-parametric testing was selected following data testing for violation 
of normality, which showed skewed data with kurtosis at all time points. A square root transformation 
was attempted to normalise distributions and eliminate outliers, but distribution remained skewed. 
Outliers were included in the analysis as non-parametric use of medians signifies outliers hold less 
influence over test results. The null hypothesis (no difference in injecting frequency at different time 
points) was tested with a non-parametric Friedman test, and subsequent post-hoc analyses using 
Wilcoxon Signed Ranked tests were run to identify where differences lay. 
Effect size r was calculated with Rosenthal’s formula  = √ [18], where Z is the post hoc Wilcoxon 
Signed Rank Test score and N is the number of observations. The coefficient r is more commonly 
used as a correlation coefficient to measure the strength of a relationship; however, it is a versatile 
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Once identified that the largest injecting frequency difference was observed between week 1 and 
week 8 of the study, this difference was used to create a new dependent variable of injecting change, 
used in the analysis both as a categorical variable, to allow for Crosstab explorations using multiple 
categorical social factors, and as a continuous variable, to allow investigation of significant differences 
between the most important categorical social factors using Mann-Whitney U tests. 
Results  
A total of 106 participants consented to treatment. Two never completed baseline measures: 1 
participant did not meet inclusion criteria and 1 participant died before starting treatment and 
completing baseline data. Of the remaining 104 consented, 94 completed treatment, but only 84 had 
completed behavioural and social data. Ten participants never commenced treatment: 3 
spontaneously cleared the infection, 4 were lost to follow-up, 2 were treated on standard pathway 
after becoming drug-free and 1 was in prison out-with the catchment area. The remaining 10 
consented participants who completed treatment had data missing for the visit 8 follow-up and were 
therefore not included in this sub-study analysis. Characteristics of participants at enrolment are 
presented in Table 1.  
Table 1 shows   for the 2*2 tables, except for Partner uses drugs, where the smallest expected 
number is too small to be informative. There are 3 variables which make significance on  : On OST, 
Has children and Has partner.  
Only 32 of the 84 participants presented a complete set of data on injecting frequency at the 8 time 
points.  A Friedman test for differences in weekly injecting frequency among the time points gave a 
significant result, χ (7) = 36.44, p< .001.  The median for week 1 was 4.5, for week 4 was 2, and 
thereafter for weeks 8 to 26 the median was 1.  The range for the 8 time points was always between 
0-14 and 0-30.  The results and effect sizes of post hoc analyses are shown in Table 2.  
Week 8 was the time point at which the largest decrease in injecting was observed. Figure 1 shows 
the difference in mean injecting frequency between week 1 and week 8 of treatment among the 
grouping variables analysed above. 
Chi-Square tests were run to explore associations between participant characteristics and injecting 
behaviour change as judged by the new variable Better or Not Better (Table 3).  Odds ratio for the 
association between having a partner who used drugs and ‘Better’ was uninformative as one of the 
2x2 factors equalled 0, causing the calculation to be impossible. The odds of reducing injecting 
behaviour were over 5 times as high for participants not on OST on week 2 compared to those who 
were on OST (OR 5.22; 95% CI 1.83-14.90; p=.002). 
A Mann-Whitney U test showed that those who had a partner who used drugs and was also on 
treatment for HCV (N=22) reduced their injecting frequency significantly more than those whose 
partner was not on treatment (N=20), Z= -2.312, p=.021, medium effect size r =0.36. The mean 
weekly injecting difference was M = 5.65 (95% CI: -0.23 to 11.54) (Figure 1). These results were 
confirmed by analysing the association between the injecting frequency difference between week 1 
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The male-female Pearson’s correlation coefficient was r = .629, p = .038, which meant that when 
males reduced their injecting, so did their female partners and vice versa. 
 
Discussion  
The findings of this paper show a significant reduction in injecting frequency between baseline, i.e. 
before the start of HCV treatment, and every other time point. The largest reduction was recorded 
between week 1 (baseline) and week 8, with injecting frequency stabilising thereafter whilst on 
treatment.  
Possible mechanisms of behaviour change were explored using baseline social factors. 
Benefits for non-OST patients 
Firstly, not being on OST on week 2 of treatment (first treatment visit recording this information) was 
found to be associated with a significant reduction in injecting frequency. It has been widely 
demonstrated that OST impacts injecting drug use [20-23]. Meta-analysis and pooled analysis of the 
effect of OST and Needle and Syringe Programmes (NSP) on incidence of HCV infections [22] 
reported a mean injecting frequency reduction of 20.8 injections per month (95% CI: -27.3 to -14.4), 
though OST did not reduce lifetime timeframe duration of injecting [23]. So it is possible that the 
patients who were on treatment for HCV and were already enrolled on OST, had previously reduced 
their injecting frequency before starting HCV treatment. Previous studies however, have attributed 
decreases in ancilliary injecting equipment and decrease in recent injecting drug use to enrolment in 
HCV treatment [16-17]. Enrolment on OST might therefore attenuate the effects of receiving HCV 
treatment on injecting behaviour. 
On the other hand, those who were not on OST on week 2 of Eradicate-C had not experienced the 
behavioural benefits of OST before their engagement with HCV treatment. It is well recognised that 
PWID are reluctant to access healthcare services, generally due to a lack of material resources, 
complicated and lengthy referral pathways, experience of stigma and poor relationship with 
healthcare providers [24-27]. For these individuals who were not on OST, engagement with HCV 
nurses might have been the only contact with any healthcare provider. Given the regular and 
considerate nature of this contact, a therapeutic relationship with the nurses providing the HCV 
treatment might have functioned as a behaviour change mechanism these patients had not 
experienced because not enrolled on OST. Therapeutic alliance was not measured in this study, yet 
previously published literature attests for the importance of this factor on healthcare outcomes relating 
to this population [28-31]. Meta-analyses have shown positive therapeutic alliance to increase 
patients’ engagement and retention within drug services, as well as motivation, treatment readiness 
and treatment experience [31]. The results of this study suggest a possible negative correlation 
between engagement in HCV treatment and injecting behaviour frequency in populations who have 
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Behaviour change in intimate partnerships 
The observed reduction in weekly injecting frequency was also linked to drug-using status of romantic 
partners. Those who had a partner who used drugs were more likely to reduce their injecting 
frequency, a reduction difference of more than 9 injections a week. This finding was surprising, as 
previous literature associated having a partner who uses drugs, in particular those injecting, with 
increased frequency of injecting and of sharing of injecting equipment [6-8, 14]. A variety of papers 
have been published on the power imbalance and social inequalities that drive injecting risk behaviour 
in heterosexual couples, in particular in women who inject drugs, who often rely on their male partner 
to acquire, prepare and inject the drugs [32-34]. Disregard of injecting risk occurs as a consequence 
of emotional closeness, intimacy, trust and commitment [14, 34-35]. Given the high level of sero-
concordance in people who inject drugs in intimate partnerships [14], the study team identified 
patients in dyadic intimate partnerships who had both been enrolled on the Eradicate-C trial. The trial 
nurses identified 22 participants in couples. The final study findings confirmed that members of 
couples both treated for HCV on Eradicate-C were significantly more likely to reduce their injecting 
than other individuals.This effect was explored through models of behaviour change explaining the 
influence of partners on each other’s health-related behaviour. The Interdependence model of couple 
communal coping and behaviour change [15], explores couple dynamics and their influence on 
motivation and health behaviour change. 
In the general population, the health benefits of being married or in a committed intimate relationship 
are well documented [14-15]. People in romantic partnerships tend to be healthier, engage with health 
care services and show a longer lifespan [15].  The role of intimate partnerships within the drug using 
population, however, has often been linked to increased risk-taking behaviour and generally has been 
viewed as a bad influence on health [14, 32-35]. Qualitative studies have shown that HCV 
management within couples could help consolidate a relationship, introducing sentiments such as 
feeling valued and cared for [14]. PWID generally experience hostile social environments, and 
intimate partnerships which involve sentiments such as those above, might represent one of the only 
types of meaningful social support and care that PWID encounter [14]. Social support is regarded as 
an essential part of HCV treatment, with many care pathways for PWID involving the role of a peer 
support worker as integral part of the treatment [36], providing empathy and trustworthiness to 
patients on treatment. However, it is not simply individualistic social support perception that has to be 
considered to explain the study findings. 
Lewis’ couples’ interdependence theory [15] explains how motivation transformation can occur when 
partners experience a health event which is not only significant for the self, but has cognitive and 
emotional significance for the relationship. The attribution of significance of the health event to the 
dyad rather than the individual is the result of automatic consideration of partnership roles, subjective 
norms, commitment, quality of the relationship, and trust [15]. HCV infection is a health threat that has 
both emotional and cognitive implications on the relationship and on each partner. These implications 
help transform motivation from ‘individual-focused’ to ‘relationship-focused’, adding a layer of complex 
interplay between intrapersonal and interpersonal behaviour change processes. Once motivation has 
become ‘relationship-focused’, couples work together through communal coping to achieve better 
health through shared action to manage the health threat [15, 37]. Communal coping requires shared 
beliefs that joint effort is advantageous to combat HCV, communication about HCV infection between 
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impacts health behaviour through the processes of outcome efficacy and couple efficacy [15, 37]. The 
couple’s belief about the effectiveness of the coping/action strategies, i.e. HCV treatment, coupled 
with the couple’s confidence about engaging in joint coping, i.e. reducing injecting frequency will 
ensure HCV is less likely to recur in the couple, will influence the behavioural outcome. The 
responsibility of the couples’ (and individual) health therefore lies equally on both partners, enabling 
the couple to become the unit for risk-reducing behaviour change [14-15]. Associations between 
changes in self-perception and self-care have been identified before [12, 38]. Often these self-
perceptions are intended as the ‘self’ as an ‘addict’ becoming the ‘self’ as a ‘patient worthy of HCV 
treatment’ [12, 14]. A similar process of psychological alteration might take place within the couple, 
with the couple’s identity changing from ‘drug-using partners’ to ‘HCV-treated partners, who coped 
with effects of treatment and achieved SVR as a unit’, presenting a shared sense of ‘self’. 
 
Reinfection 
One of the main challenges of treating patients with ongoing injecting risk behaviour is the risk of 
reinfection following successful treatment (defined as 12 weeks post-treatment aviremia). Published 
literature shows that people who have previously been infected (and been treated) are more likely to 
become infected with HCV once again compared to people who are HCV-naïve [39-42]. In a meta-
analysis of 59 studies, Simmons and colleagues [42] report pooled HCV recurrence rates for low-risk, 
high-risk and HIV co-infected populations after treatment during IFN-era: respectively 1.85/1000 
person years of follow-up (PYFU), 22.32/1000 PYFU and 32.02/1000 PYFU. These recurrence rates 
led to a summary 5-year risk of 0.95%, 10.67% and 15.02% respectively [42]. 
Reducing injecting risk behaviour is the first step to reduce the risk of HCV reinfection after successful 
treatment. Reducing injecting behaviour within romantic partnerships could have particular benefits in 
preventing reinfection, given the widespread injecting equipment sharing practices among sexual 
partners. The observed injecting frequency reduction within couples during treatment in this study, 
would seem to suggest a transitive relation between treating couples in a romantic partnership and a 
reduced risk of reinfection, with the reduced injecting behaviour as the linking factor. This will be 
investigated in future reinfection studies. 
 
Conclusions 
This study shows that treating a hard-to-reach population for HCV infection is not only possible, but 
also suggests health benefits beyond treatment of HCV alone. A significant reduction in injecting 
behaviour was observed in people who are not on OST and/or couples on HCV treatment when 
partners are sero-concordant compared to the rest of the sample A complex interplay of relationship-
focused motivation transformation, outcome efficacy, couple efficacy and communal coping might 
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A few limitations are recognised within the study. Firstly, albeit the initial sample size seemed 
promising, missing data at different time points and the selection of different grouping variables 
considerably reduced the sample size for some of the analyses (N=42). However, the majority of 
clinical trials experience missing data [43] and the analyses were performed taking this into 
consideration. Two social variables did show a significant difference between those retained in the 
study and those lost, suggesting those who were lost to follow-up were less likely to have romantic or 
family social connections. This observation gives even more importance to this paper’s findings of 
being on HCV treatment with a romantic partner, as it would suggest important social connections can 
influence engagement with research and healthcare professionals. Secondly, the effect of the results 
might not be as large for DAA treatment. IFN-based treatment was notoriously harsh and both 
therapeutic alliance in non-OST patients and communal coping within the couples might have 
developed strongly as a consequence of this. With the advent of DAA treatment, relationship-focused 
motivation and communal coping might become less necessary and prominent. Fewer side effects, 
significantly shorter treatment times and ease of treatment (oral treatment) will render the 
development of communal coping somewhat unnecessary, therefore reducing the likelihood of 
couples influencing each others’ health-enhancing behaviour change. Shorter treatment times and 
ease of treatment might also affect the quality of the therapeutic relationship established between 
hard-to-reach patients and healthcare provider. Once again, this might impact on the hereby observed 
injecting behaviour change. However, the notion of HCV treatment alone, rather than the hardship 
endured or the length of treatment time, might be enough to kick-start the motivational transformation 
within an intimate partnership and effects on communal coping and risk-behaviour reduction could still 
be observed in the DAA treatment era. Further research on similar populations being treated with IFN-
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TABLES 
Table 1: Characteristics of participants at enrolment on Eradicate-C study (study population 
and those lost to follow-up or with missing behavioural data). 
Characteristic Study population
(N=84) 
Lost to Follow-up 




Female Sex (%) 26 (31) 2 (10) 3.60 5.4 
Age, median (IQR) 34 (23-45) 33 (25.25-40.75)   
Legal situation: none (%) 49 (58.3) 11 (55) 0.07 8.5 
Living situation     
Homeless (%) 16 (19) 6 (30) 1.16 4.2 
Living in own or rented 
accommodation (%) 
61 (72.6) 13 (65) 0.46 5.8 
Living alone (%) 38 (45.2) 12 (60) 1.41 9.6 
Living with partner (%) 25 (29.8) 4 (20) 0.77 5.6 
Living with parents (%) 12 (14.3) 1 (5) 1.27 2.5 
Living with other drug 
users (%) 
30 (35.7) 5 (25) 0.83 6.7 
Romantic relationships     




Partner uses drugs (% of 
Has partner) 
34 (81) 4 (80) Fisher 
p=1 
Too small 






    
EQ5D Health state score, 
median (IQR) 
50 (20-80) 45 (20-70)   




Methadone dose, median 
(IQR) 
70 (45-95) 75 (61-89)   
Weekly injecting 
frequency, Mean (STD) 
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Table 2: Post Hoc comparisons for weekly injecting frequency between week 1 of treatment 
and all subsequent repeated measurement every 4 weeks (N=32). 
 Z p *   r † 
Weeks 1-4 -3.534 < .001* -.63 
Weeks 1-8  -5.459 < .001* -.97 
Weeks 1-12 -5.265 < .001* -.93 
Weeks 1-16 -4.759 < .001* -.84 
Weeks 1-20 -3.768 < .001* -.67 
Weeks 1-24 -3.225 .001* -.57 
Weeks 1-26 -4.495 < .001* -.80 
* Wilcoxon Signed Rank tests Significant at p < .007 with Bonferroni correction 












Table 3: Chi Square Tests for association between injecting behaviour change variable 
(better/not better†) and psychosocial factors. 
Characteristic (N) χ2 (df) p * Fisher’s Exact Test * 
Legal situation (82) 4.254 (4) .373 na 
Living situation (82) 1.361 (3) .715 na 
Accommodation (82) .04 (2) .98 na 
Living with other drug users (79) 2.007 (1) .157 .21 
Romantic relationships    
Has partner (42) .023 (1) .880 1 
Partner uses drugs* (42) 4.43 (1) .035* .043* 
Has children (82) .067 (1) .795 .813 
Healthcare-related measures    
EQ5D Mobility (80) .05 (1) .823 1 
EQ5D Self-care (80) 1.088 (1) .297 .368 
EQ5D Activity (79) .621 (2) .733 na 
EQ5D Pain (80) .905 (2) .636 na 
EQ5D Anxiety (80) 1.159 (2)  .56 na 
On OST week 2* (82) 10.412 (1) .001* .003* 
* Significant at p < .05 
na: not available 
† The difference between week 1 and week 8 injecting frequency was computed and categorised as ‘Better’ for a 
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FIGURE LEGENDS 
Figure 1: Injecting frequency change by grouping: * Significant at p < .05 
 
 
 
 
 
